Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DZD1516 in Metastatic HER2 Positive Breast Cancer
NCT04509596Phase 1Completed
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Sep 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of DZD1516 in HER2-positive breast cancer (3 arms), sponsored by Dizal Pharmaceutical Co., Ltd. Primary endpoints: Incidence of adverse events at 1 year, Incidence of dose limiting toxicities at 21 days and 2 more. Started Sep 2020; status: completed.
02
Drugs
DZD1516
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04509596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04509596.